Rahul D. Ballal, Director at Enliven Therapeutics, Inc. (ELVN), sold 70,068 shares at $21.01 ($1.6M) on 2024-04-10, disclosed to the SEC on 2024-04-12.
Scheduled sale ($1.6M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.01 | 13,600 | $286K | 17.4% |
| 2 | $23.14 | 30,300 | $701K | 42.7% |
| 3 | $25.00 | 20,032 | $501K | 30.5% |
| 4 | $25.21 | 3,068 | $77K | 4.7% |
| 5 | $25.21 | 3,068 | $77K | 4.7% |
| Total | $23.44 avg | 70,068 |
| $1.6M |
| 100% |
| Filing → |
| ELVN | SELL | 2024-04-08 | $133K | — | Filing → |
| ELVN | SELL | 2024-04-03 | $124K | — | Filing → |
| ELVN | SELL | 2024-03-22 | $509K | — | Filing → |